| Stereochemistry | ABSOLUTE |
| Molecular Formula | C59H96O26 |
| Molecular Weight | 1221.3779 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 33 / 33 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@H](OC[C@H]3O[C@@H](OC(=O)[C@]45CCC(C)(C)C[C@H]4C6=CC[C@@H]7[C@@]8(C)CC[C@H](O[C@@H]9OC[C@H](O)[C@H](O)[C@H]9O[C@@H]%10O[C@@H](C)[C@H](O)[C@@H](O)[C@H]%10O)[C@@](C)(CO)[C@@H]8CC[C@@]7(C)[C@]6(C)CC5)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=RYHDIBJJJRNDSX-MCGLQMIESA-N
InChI=1S/C59H96O26/c1-24-34(63)38(67)42(71)49(78-24)83-46-29(20-60)80-48(45(74)41(46)70)77-22-30-37(66)40(69)44(73)51(81-30)85-53(75)59-17-15-54(3,4)19-27(59)26-9-10-32-55(5)13-12-33(56(6,23-61)31(55)11-14-58(32,8)57(26,7)16-18-59)82-52-47(36(65)28(62)21-76-52)84-50-43(72)39(68)35(64)25(2)79-50/h9,24-25,27-52,60-74H,10-23H2,1-8H3/t24-,25-,27-,28-,29+,30+,31+,32+,33-,34-,35-,36-,37+,38+,39+,40-,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51-,52-,55-,56-,57+,58+,59-/m0/s1
| Molecular Formula | C59H96O26 |
| Molecular Weight | 1221.3779 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 33 / 33 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Mice were given an oral dose of kalopanaxsaponin B (5 mg/kg).
Route of Administration:
Oral
Mouse peritoneal macrophages were incubated with FITC-conjugated LPS (10 ug/ml) for 30 min in the presence of 5 or 10 uM of kalopanaxsaponin B at room temperature. Kalopanaxsaponin B inhibited the expression of TNF-alpha, IL-1beta, iNOS and COX-2 and inhibited activation of IRAK1, IKK-beta, NF-kappaB and MAP kinases (ERK, JNK, p-38).
